Braf V600e
Entity.
- Evidence
- 41 documents · 16 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 2 Apr 2026, last seen 8 Oct 2026
- Measured
- 7% of mentions say something specific about it; the rest only name it
- As of
- 16 Oct 2026
Where this comes from
- Anticancer Drugs · 2026-09-30 · Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case r… (opens the source in a new tab)
- Clinical Colorectal Cancer · 2026-09-15 · Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A … (opens the source in a new tab)
- Annals of Oncology · 2026-09-06 · BREAKWATER trial shows new first-line option for BRAF V600E-mutant metastatic colorectal cancer (opens the source in a new tab)
- Crc-Digest · 2026-09-03 · Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC (opens the source in a new tab)
- Clin Colorectal Cancer · 2026-09-02 · Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer. (opens the source in a new tab)
- Crc-Digest · 2026-08-25 · Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China (opens the source in a new tab)